Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protocadherin gamma subfamily B, 9 pseudogene (PCDHGB9P) is a non-coding sequence in the human genome classified as a pseudogene, meaning it resembles a gene coding for a protein (in this case, within the protocadherin gamma gene cluster) but is predicted not to produce a functional protein. It has been assigned the synonym PSI6. There is no evidence that this pseudogene acts as a therapeutic target, nor does it encode a receptor, enzyme, or other druggable protein. No biological, pathogenic, or therapeutic significance is currently attributed to PCDHGB9P[1][3][5]. In summary, PCDHGB9P is a pseudogene—an inactive gene remnant—which means it is not considered a therapeutic target or functionally relevant protein, thus most entries (such as drugs, mechanism, biomarker, etc.) should be returned as null or not applicable[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protocadherin gamma subfamily B, 9 pseudogene (PCDHGB9P).